Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors

Journal of Neuro-Oncology

Volumn 103, Issue 1, 2011, Pages 147-153

  Ridola, Vita ^a   Barone, Giuseppe ^a   Lazzareschi, Ilaria ^a   Ruggiero, Antonio ^a   Rizzo, Daniela ^a   Riccardi, Riccardo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Brain tumors; Lymphopenia; Prolonged low dosage schedule; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CANCER RADIOTHERAPY; CHILD; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPENDYMOMA; FEASIBILITY STUDY; FEMALE; GLIOMA; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; INFANT; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MENINGOENCEPHALITIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRESCHOOL CHILD; SKIN DISEASE; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR RECURRENCE; VIRAL GASTROENTERITIS; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959924879     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0371-x     Document Type: Article

References (25)

1. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS (1992) Phase I trial of temozolomide. Br J Cancer 65:287-291
2. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771 (Pubitemid 29415233)
3. Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom children's cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol 20:4684-4691 (Pubitemid 36025286)
4. Verschuur AC, Grill J, Vassal G et al (2004) Temozolomide in pediatric high-grade glioma: a key for combination therapy ? Br J Cancer 91:425-429 (Pubitemid 39093558)
5. Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25: 372-378 (Pubitemid 36569968)
6. Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49:808-811 (Pubitemid 47519517)
7. Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110:1542-1550 (Pubitemid 47463069)
8. Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 11:69-79
9. Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide- refractory glioblastoma. Oncol Rep 16:1117-1121
10. Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330-337
11. Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011 (Pubitemid 36560766)
12. Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346 (Pubitemid 36951001)
13. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206 (Pubitemid 32176298)
14. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321:265-275 (Pubitemid 46456967)
15. Virrey JJ, Golden EB, Sivakumar W et al (2009) Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol 95:13-22
16. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
17. http://ctep.cancer.gov/forms/CTCAE.pdf. Accessed January 1, 2004
18. Sterba J, Pavelka Z, Slampa P (2002) Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49:117-120 (Pubitemid 34493673)
19. Su YB, Sohn S, Krown SE et al (2004) Selective CD4? lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610-616 (Pubitemid 41095063)
20. Ruggiero A, Cefalo G, Garré ML et al (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77:89-94 (Pubitemid 43870566)
21. Brock CS, Newlands ES, Wedge SR et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367 (Pubitemid 28450038)
22. Khan RB, Raizer JJ, Malkin MG et al (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4:39-43 (Pubitemid 34269465)
23. Stupp R, Dietrich P, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382 (Pubitemid 34177445)
24. Ganière V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 3:339-343 (Pubitemid 43871544)
25. Baruchel S, Diezi M, Hargrave D et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42:2335-2342 (Pubitemid 44316901)